A Canadian Open-Label, Multicenter, Expanded Access Study of Oral Nilotinib in Adult Patients With Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase, or Chronic Phase.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Registrational
- 12 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 Jan 2007 New trial record.